Rapid universal detection of contaminating microbes through micro-scale culture

Overview

This technology addresses the critical need for rapid, sensitive, and affordable microbial contamination detection in medical fluids such as blood, plasma, and platelet products. Current clinical microbiology methods rely on milliliter-scale broth culture with visual turbidity detection, which requires dedicated instrumentation and prolonged incubation times. Molecular amplification techniques such as PCR offer sensitivity but are too costly and complex for routine, point-of-use deployment.

The proposed solution integrates three established principles into a single streamlined workflow: microfilter concentration of organisms, microliter-volume culture, and lateral-flow immunoassay detection. By miniaturizing culture to the microfluidic scale, the platform achieves natural biological amplification of target organisms while remaining inexpensive and simple to operate. The end product targets a per-use cost of approximately $1, making it suitable for broad clinical and field deployment.

Technical specifications

Key features:

• Microfilter concentration captures and concentrates microbial cells from larger sample volumes into a small working volume
• Microliter-scale culture enables rapid incubation by reducing diffusion distances and accelerating microbial growth to detectable levels
• Lateral-flow immunoassay detects low-level microbial growth that is not visually discernable, using inexpensive strip-based readout
• Broad-range antibody panels differentiate between Gram-positive bacteria, Gram-negative bacteria, and fungal contaminants in a single test
• Single-organism sensitivity achieved through natural biological amplification rather than in vitro molecular methods
• Low-complexity design eliminates the need for PCR instrumentation, dedicated culture readers, or specialized training

Technology readiness level

This technology is at an early-to-mid stage of development. The individual components—microfilter concentration, microscale culture, and lateral-flow immunoassay—are well-established principles in clinical microbiology and bioengineering. The innovation lies in their integration into a unified, low-cost platform.

Validation is being conducted through a collaboration between a biomedical engineering laboratory, which oversees microfluidic integration of the test components, and a clinical microbiology laboratory, which validates performance against the rigorous criteria used in clinical testing environments. Future work will focus on demonstrating single viable cell detection across bacterial and fungal species, confirming differentiation between Gram categories, and establishing reproducibility and shelf-life characteristics required for clinical translation.